Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed multiple myeloma Stage II disease
Symptomatic due to progressive disease OR Stage III disease No stage I multiple myeloma or
smoldering myeloma

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-3 Life expectancy:
More than 4 months Hematopoietic: Absolute granulocyte count at least 1,500/mm3* Platelet
count at least 100,000/mm3* *Unless due to multiple myeloma Hepatic: Bilirubin no greater
than 2.0 mg/dL ALT and AST no greater than 3 times upper limit of normal (ULN) Alkaline
phosphatase no greater than 3 times ULN Renal: Elevated creatinine allowed Cardiovascular:
LVEF at least 50% by MUGA or ECHO No active angina No myocardial infarction within the
past 6 months Other: Not pregnant or nursing Negative pregnancy test Fertile patients must
use effective contraception at least 4 weeks prior to, during, and for at least 4 weeks
after study No grade II or greater pre-existing neuropathy No other concurrent or prior
active malignancy within the past 2 years except adequately treated non-melanoma skin
cancer or carcinoma in situ of the cervix Prior T1a or T1b prostate cancer (detected
incidentally at transurethral resection of prostate (TURP) and comprising less than 5% of
resected tissue) allowed if PSA normal since TURP HIV negative No AIDS-related illness No
other medical condition that would preclude study

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
chemotherapy for multiple myeloma Endocrine therapy: No more than 1 course of prior pulse
dexamethasone Prior steroids of less than 1 month duration for emergent indications or
life-threatening lesions (e.g., hypercalcemia or spinal cord compromise) allowed
Radiotherapy: Prior radiotherapy allowed Surgery: Not specified